Bassem Chaar, MD
Hematology & Oncology · Chicago Ridge, ILNPI 1497783179
Payments from drug & device makers
Across 180 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$842
- Merck$387
- AbbVie$349
- Pfizer$260
- E.r. Squibb & Sons, L.L.C.$232
- Global Blood Therapeutics, Inc.$125
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,56996%
- Education$1354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 48 | $842 |
| Merck | 18 | $387 |
| AbbVie | 18 | $349 |
| Pfizer | 15 | $260 |
| E.r. Squibb & Sons, L.L.C. | 12 | $232 |
| Global Blood Therapeutics, Inc. | 6 | $125 |
| Sobi, Inc | 2 | $119 |
| AstraZeneca(2 entities) | 2 | $118 |
| Gilead(2 entities) | 6 | $113 |
| Agios Pharmaceuticals, Inc. | 5 | $111 |
| GSK | 3 | $86 |
| Johnson & Johnson(2 entities) | 4 | $85 |
| Bristol Myers Squibb | 3 | $63 |
| Genentech USA, Inc. | 3 | $55 |
| Myriad Genetic Laboratories, Inc. | 2 | $54 |
| Amneal Pharmaceuticals LLC | 2 | $53 |
| Eisai Inc. | 2 | $47 |
| G1 Therapeutics, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Array Biopharma Inc | 2 | $40 |
| Astellas Pharma US Inc | 2 | $37 |
| Beigene USA, Inc. | 2 | $34 |
| Puma Biotechnology, Inc. | 1 | $32 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| Tempus AI, Inc | 1 | $28 |
| CTI Biopharma Corp. | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Dova Pharmaceuticals | 1 | $22 |
| GE HealthCare | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Medtronic | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,705 in reported general payments places this provider in the 40th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 81 | $971,588 |
| PomalystPomalidomide | 27 | $587,279 |
| CalquenceAcalabrutinib Maleate | 33 | $500,487 |
| BrukinsaZanubrutinib | 27 | $399,030 |
| VerzenioAbemaciclib | 25 | $397,105 |
| CabometyxCabozantinib S-Malate | 12 | $292,385 |
| XtandiEnzalutamide | 19 | $253,818 |
| TasignaNilotinib Hcl | 13 | $241,790 |
| VenclextaVenetoclax | 22 | $167,547 |
| GleevecImatinib Mesylate | 14 | $140,106 |
| EliquisApixaban | 145 | $126,247 |
| Imatinib Mesylate | 11 | $52,755 |
| Abiraterone Acetate | 37 | $45,942 |
| XareltoRivaroxaban | 39 | $29,145 |
| Dexamethasone | 149 | $2,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $63 | $971,58881 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $232 | $587,27927 claims |
| AstraZenecaCalquence | $118 | $500,48733 claims |
| Beigene USA, Inc.Brukinsa | $34 | $399,03027 claims |
| Lilly USA, LLCVerzenio | $42 | $397,10525 claims |
| NovartisTasigna, Gleevec | $842 | $381,89627 claims |
| Astellas Pharma US IncXtandi | $37 | $253,81819 claims |
| AbbVieVenclexta | $349 | $167,54722 claims |
| PfizerEliquis | $260 | $126,247145 claims |
| Johnson & JohnsonXarelto | $85 | $29,14539 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $44957 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Chicago Ridge
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.